Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

June 8, 2018: By Jon Swedien

Ophthotech Corporation has signed an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania to develop and commercialize a gene therapy, the New York-based company announced June 7.

Ophthotech and the universities plan to co-develop an adeno-associated virus (AAV) product to treat rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP).

RHO-adRP is an orphan monogenic disease characterized by progressive and severe vision loss, leading to blindness.

Ophthotech said preclinical anatomical and functional proof-of-concept studies have demonstrated promising results in a canine disease model.

Ophthotech and Penn also agreed to a master-sponsored research deal, facilitated by the Penn Center for Innovation, the company said. Under this deal, Ophthotech and Penn plan to conduct preclinical and natural history studies. In parallel with the sponsored research, Ophthotech plans to start investigational new drug-enabling activities and expects to initiate a Phase I/II trial in early 2020, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023